TY - JOUR
T1 - Intracavitary brachytherapy for carcinoma of the esophagus
AU - Micaily, Bizhan
AU - Miyamoto, Curtis T.
AU - Freire, Jorge E.
AU - Brady, Luther W.
PY - 1997/5
Y1 - 1997/5
N2 - Local control of unresectable esophageal carcinomas remains a significant problem in spite of aggressive treatments. External beam radiation therapy, chemotherapy, and combined modality treatment have all been employed with limited success. Here we review the existing literature and our own experience with external beam radiation followed by low-dose- rate or high-dose-rate intracavitary radiation for carcinoma of esophagus. The addition of intracavitary brachytherapy to external beam irradiation is well tolerated, causes no significant toxicity, and improves local control. Low-dose-rate intracavitary boost compared to high-dose-rate intracavitary boost has the advantage of a greater margin of safety, requires a single application, does not require highly sophisticated computerized technology, and is accompanied with fewer high-grade toxicities. Combined modality therapy consisting of concomitant infusional chemotherapy, external beam irradiation, and low-dose-rate intracavitary boost needs to be investigated.
AB - Local control of unresectable esophageal carcinomas remains a significant problem in spite of aggressive treatments. External beam radiation therapy, chemotherapy, and combined modality treatment have all been employed with limited success. Here we review the existing literature and our own experience with external beam radiation followed by low-dose- rate or high-dose-rate intracavitary radiation for carcinoma of esophagus. The addition of intracavitary brachytherapy to external beam irradiation is well tolerated, causes no significant toxicity, and improves local control. Low-dose-rate intracavitary boost compared to high-dose-rate intracavitary boost has the advantage of a greater margin of safety, requires a single application, does not require highly sophisticated computerized technology, and is accompanied with fewer high-grade toxicities. Combined modality therapy consisting of concomitant infusional chemotherapy, external beam irradiation, and low-dose-rate intracavitary boost needs to be investigated.
KW - Brachytherapy/adverse effects
KW - Carcinoma/radiotherapy
KW - Clinical Trials as Topic
KW - Esophageal Neoplasms/radiotherapy
KW - Humans
KW - Radiation Dosage
KW - Survival Rate
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=0030964825&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1098-2388(199705/06)13:3<185::AID-SSU5>3.0.CO;2-3
DO - 10.1002/(SICI)1098-2388(199705/06)13:3<185::AID-SSU5>3.0.CO;2-3
M3 - Article
C2 - 9143056
AN - SCOPUS:0030964825
SN - 8756-0437
VL - 13
SP - 185
EP - 189
JO - Seminars in Surgical Oncology
JF - Seminars in Surgical Oncology
IS - 3
ER -